The article discusses a study "GLP-1R Agonists Promote Normal and Neoplastic Intestinal Growth Through Mechanisms Requiring Fgf7," conducted by reasercher J.A. Koehler and colleagues, published in the journal "Cell Metabolism" which reveal that agonists of the glucagon-like peptide-1 receptor (GLP1R) are used to treat type 2 diabetes.